Ronald Renaud

Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information.

JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics.

Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA.

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

Newton-Wellesley Hospital Corp. provides health care services. Its services include medical, surgical and diagnostic services. The company was founded in 1881 and is headquartered in Newton, MA.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA.

Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021.

Bain Capital Holdings LP is an investment holding company. The company is headquartered in Boston, MA.

Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts.